AMSBIO Sponsor Poster Prize at Beatson Cancer Conference
AMSBIO, a provider of cutting-edge life science technologies and services for accelerating discovery in cancer research, has continued its sponsorship of the annual poster prize at the Beatson International Cancer Conference (7–10 July 2013).
The two winners of the Poster Prize for the best presented and most interesting posters, were this year named as Dr Thomas R. Cox and co-researchers** for their work on ‘Deep proteomic analysis of the hypoxic secretome lysyl oxidase as a critical mediator of metastatic lesion formation in bone’, and Dr Jean Albrengues & co-researchers*** for their work on ‘Production of LIF cytokine by cancer cells and fibroblasts contributes to the establishment of a pro-invasive tumour microenvironment’.
As one of Cancer Research UK’s core-funded institutes, the Beatson Institute (www.beatson.gla.ac.uk/) performs a programme of world-class science directed at understanding key aspects of cancer cell behaviour, and tries to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University’s Institute of Cancer Sciences.
AMSBIO is a rapidly growing company focused on the supply and development of products and technology for cancer research with emphasise on apoptosis, DNA damage and repair, and cancer cell function and behavior. AMSBIO supplies focused research products for cancer research that allow researchers to study cancer cell function and behavior including in angiogenesis, cell invasion and PARP and PARG research. Together with specifically designing assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior, AMSBIO is establishing itself as a leading international provider of cancer research tools and services.
** Thomas R Cox1,2, Erwin M Schoof3, Demelza Bird2, Norain Ab Latif4, Antika Agrawal4, Holly R Evans4, Iain D Huggins4, Robin MH Rumney4, Georgina Lang2, Rune Linding3, Alsion Gartland4 and Janine T Erler1,2.
1 Biotech Research & Innovation Centre (BRIC), University of Copehagen, Denmark
2 Cancer Research UK Tumour Cell Signalling Unit, The Institute of Cancer Researh, London, UK
3 Cellular Signal Integration Group, Department of Systems Biology, Technical University of Denmark, Denmark.
4 The Mellanby Centre for Bone Research, The University of Sheffield, Sheffield, UK
*** Jean Albrengues1, Isabelle Bourget1, Catherine Pons1, Vincent Butet2, Sophie Tartare-Deckert3, Chloe Feral1, Guerrino Meneguzzi1 and Cedric Gaggioli1
1 INSERM, U1081, CRNS, UMR7284, Institute for Research on Cancer & Aging in Nice (IRCAN), University of Nice Sophia Antipolis, Medical School, 28 Avenue de Valombrose, F-06107, Nice, France.
2 Pathological anatomy & cytology laboratory, 270 Avenue Sainte-Marguerite, F-06200, Nice, France.
3 INSERM, U1065, Mediterranean Centre for Molecular Medicine (C3M), University of Nice Sophia Antipolis, Nice, France.
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients.
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
A quarterly series of articles about responsible supply chain management from the PSCI.
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet...
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region.
News Medicines for All receive $18.7 million grant for expansion of global access to lifesaving medicationFunded by the Bill & Melinda Gates Foundation, the Virginia Commonwealth University-based research-related institute will use the grant to expand on its current capabilities of bringing lifesaving medications around the world, as well as working on 14 ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance